The use of sacubitril/valsartan appears feasible and safe in recipients of left ventricular assist devices, reducing the need for blood pressure-lowering agents and improving quality of life.

SGLT2 inhibitors represent one of the most remarkable therapeutic developments in heart failure care, transitioning from diabetes medications to cornerstone heart failure therapy through an evolutionary research process.

A new experimental therapy helps restore the heart’s flexibility in models of stiffened heart failure. Michael Gotthardt and his colleagues at the Max Delbrück Center are working with U.S. researchers

A promising “two-in-one” experimental drug could tackle both type 2 diabetes and heart disease by slashing cholesterol and inflammation, potentially offering a powerful new way to protect the heart and improve metabolism.

Researchers say GLP-1 drugs prescribed for weight loss like Ozempic and Mounjaro are more effective at reducing heart health risks in people with type 2 diabetes than other types of glucose-lowering medications.